Efficacy and Safety Outcomes
GUSTO, bleeding
EVENTS, BLEEDING
The primary efficacy and safety outcomes in this analysis were identical to those of the CHANCE-2 trial.The primary safety outcome was severe or moderate bleeding events within 3 months, defined by the criteria from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) trial.